What is HC Wainwright’s Estimate for ANRO Q1 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Alto Neuroscience in a research report issued on Monday, April 7th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.45) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.32) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($3.04) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($2.99) EPS and FY2029 earnings at ($1.69) EPS.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09.

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Stock Up 3.1 %

Alto Neuroscience stock opened at $2.11 on Thursday. The firm has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $4.84. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $17.55. The firm has a market capitalization of $57.20 million, a price-to-earnings ratio of -0.83 and a beta of 2.16.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares in the last quarter. Jane Street Group LLC bought a new position in Alto Neuroscience in the 3rd quarter worth about $124,000. Wells Fargo & Company MN raised its holdings in shares of Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after acquiring an additional 3,139 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after acquiring an additional 3,629 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Alto Neuroscience during the fourth quarter worth about $74,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.